PT2262785E - Derivados de benzofurano, benzotiopeno, benzotiazol como moduladores de fxr - Google Patents

Derivados de benzofurano, benzotiopeno, benzotiazol como moduladores de fxr Download PDF

Info

Publication number
PT2262785E
PT2262785E PT97318554T PT09731855T PT2262785E PT 2262785 E PT2262785 E PT 2262785E PT 97318554 T PT97318554 T PT 97318554T PT 09731855 T PT09731855 T PT 09731855T PT 2262785 E PT2262785 E PT 2262785E
Authority
PT
Portugal
Prior art keywords
fxr modulators
benzofurane derivatives
benzofurane
derivatives
fxr
Prior art date
Application number
PT97318554T
Other languages
English (en)
Inventor
Francis Contard
Ingo Kober
Didier Roche
Saumitra Sengupta
Gisèle Mautino
Serge Christmann-Franck
Ramesh Sistla
Gummadi Venkateshwar Rao
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39769187&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2262785(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PT2262785E publication Critical patent/PT2262785E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT97318554T 2008-04-18 2009-03-30 Derivados de benzofurano, benzotiopeno, benzotiazol como moduladores de fxr PT2262785E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08300183A EP2110374A1 (en) 2008-04-18 2008-04-18 Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators

Publications (1)

Publication Number Publication Date
PT2262785E true PT2262785E (pt) 2015-04-29

Family

ID=39769187

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97318554T PT2262785E (pt) 2008-04-18 2009-03-30 Derivados de benzofurano, benzotiopeno, benzotiazol como moduladores de fxr

Country Status (27)

Country Link
US (1) US8575161B2 (pt)
EP (2) EP2110374A1 (pt)
JP (2) JP5616326B2 (pt)
KR (1) KR101662853B1 (pt)
CN (1) CN101990535B (pt)
AR (1) AR071207A1 (pt)
AU (1) AU2009238015B2 (pt)
BR (1) BRPI0911243B8 (pt)
CA (1) CA2721591C (pt)
CO (1) CO6311099A2 (pt)
CY (1) CY1116333T1 (pt)
DK (1) DK2262785T3 (pt)
EA (1) EA020454B1 (pt)
EC (1) ECSP10010615A (pt)
ES (1) ES2531006T3 (pt)
HK (1) HK1155741A1 (pt)
HR (1) HRP20150319T1 (pt)
IL (1) IL208322A (pt)
MX (1) MX2010011292A (pt)
MY (1) MY156530A (pt)
NZ (1) NZ589327A (pt)
PL (1) PL2262785T3 (pt)
PT (1) PT2262785E (pt)
SI (1) SI2262785T1 (pt)
UA (1) UA104140C2 (pt)
WO (1) WO2009127321A1 (pt)
ZA (1) ZA201008243B (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3205644A1 (en) 2005-12-29 2017-08-16 Celtaxsys Inc. Diamine derivatives as inhibitors of leukotriene a4 hydrolase
EP2110374A1 (en) * 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
UY32481A (es) * 2009-03-10 2010-09-30 Takeda Pharmaceutical Derivados de benzofurano
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8729084B2 (en) 2010-05-06 2014-05-20 Bristol-Myers Squibb Company Benzofuranyl analogues as GPR119 modulators
BR112012028445A2 (pt) 2010-05-06 2016-07-19 Bristol Myers Squibb Co compostos de heteroarila bicíclica como moduladores de gpr119
TW201204733A (en) 2010-06-25 2012-02-01 Kowa Co Novel condensed pyridine or condensed pyrimidine derivative, and medicinal agent comprising same
CA2822357A1 (en) 2010-12-22 2012-06-28 Abbvie Inc. Hepatitis c inhibitors and uses thereof
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
WO2014006637A2 (en) * 2012-07-02 2014-01-09 Symed Labs Limited Improved process for preparing benzofuran-2-carboxamide derivatives
CN102993186B (zh) * 2012-12-20 2015-11-18 北京海步国际医药科技发展有限公司 一种新型的哌嗪衍生物
RU2686101C2 (ru) 2013-03-12 2019-04-24 Селтакссис, Инк. Способы ингибирования лейкотриен- а4-гидролазы
MX2015011677A (es) 2013-03-14 2016-07-08 Celtaxsys Inc Inhibidores de leucotrieno a4 hidrolasa.
EP2968265A4 (en) 2013-03-14 2016-12-28 Celtaxsys Inc INHIBITORS OF THE LEUKOTRIEN A4 HYDROLASE
EP2970309A4 (en) 2013-03-14 2016-11-09 Celtaxsys Inc INHIBITORS OF LEUCOTRIENE A4 HYDROLASE
EP3711762A1 (en) 2013-09-11 2020-09-23 INSERM (Institut National de la Santé et de la Recherche Médicale) A farnesoid x receptor agonsits foruse and pharmaceutical compositions for the treatment of chronic hepatitis b virus infection
PE20180027A1 (es) 2015-02-06 2018-01-09 Intercept Pharmaceuticals Inc Composiciones farmaceuticas para terapia combinada
EP3277286B1 (en) 2015-03-31 2021-04-21 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
US10894054B2 (en) 2015-04-07 2021-01-19 Intercept Pharmaceuticals, Inc. FXR agonist compositions for combination therapy
CN104926804B (zh) * 2015-06-04 2019-01-25 天津渤海职业技术学院 一类具有抗肿瘤作用的化合物、其制备方法和用途
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
PT3730487T (pt) 2016-06-13 2022-07-22 Gilead Sciences Inc Derivados de azetidina como moduladores de fxr (nr1h4)
CN109906223A (zh) 2016-10-04 2019-06-18 英安塔制药有限公司 异噁唑类似物作为fxr激动剂及其使用方法
CN108017636A (zh) * 2016-11-04 2018-05-11 合帕吉恩治疗公司 作为fxr调节剂的含氮杂环化合物
US20180280394A1 (en) 2017-03-28 2018-10-04 Gilead Sciences, Inc. Methods of treating liver disease
US20210085662A1 (en) 2017-03-30 2021-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses
EP3801559A4 (en) 2018-05-31 2022-03-02 Celltaxis, LLC METHOD FOR REDUCING LUNG EXACERBATIONS IN PATIENTS SUFFERING FROM RESPIRATORY DISEASE
CA3124702A1 (en) 2019-01-15 2020-07-23 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
CA3129949C (en) 2019-02-19 2024-04-30 Gilead Sciences, Inc. Solid forms of fxr agonists
US11555032B2 (en) 2019-05-13 2023-01-17 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
BR112021024109A2 (pt) 2019-05-30 2022-03-22 Intercept Pharmaceuticals Inc Composições farmacêuticas compreendendo um agonista fxr e um fibrato para uso no tratamento de doença hepática colestática
MX2022000742A (es) 2019-07-18 2022-02-14 Enyo Pharma Metodo para disminuir los efectos adversos del interferon.
MX2022008062A (es) 2020-01-15 2022-07-27 Inst Nat Sante Rech Med Uso del agonista fxr para el tratamiento de una infeccion por el virus de la hepatitis d.
AU2022208190A1 (en) * 2021-01-14 2023-07-06 Enyo Pharma Method for treating chronic kidney diseases
JP2024502673A (ja) 2021-01-14 2024-01-22 ウエヌイグレックオ・ファーマ Ｈｂｖ感染の処置のためのｆｘｒアゴニストとｉｆｎの相乗効果
AU2022256650A1 (en) * 2021-04-16 2023-12-07 Beijing Best Pathway Management Consulting Center (Limited Partnership) Fxr regulator, preparation method therefor, pharmaceutical composition thereof and use thereof
TW202308629A (zh) 2021-04-28 2023-03-01 法商Ｅｎｙｏ製藥公司 使用fxr激動劑作為組合治療以增強tlr3激動劑之療效
CN113214200B (zh) * 2021-05-26 2022-03-29 神隆医药（常熟）有限公司 一种以铜催化偶联反应制备维拉佐酮中间体的方法
JP2024529298A (ja) 2021-07-09 2024-08-06 プレキシウム インコーポレイテッド Ｉｋｚｆ２を調節するアリール化合物及び医薬組成物
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
CN118742306A (zh) * 2022-01-17 2024-10-01 和博医药有限公司 苯并噻唑-哌嗪基-噁唑化合物的固体形式及其使用方法
WO2024032530A1 (zh) * 2022-08-11 2024-02-15 江苏恩华药业股份有限公司 芳杂环并环己烷基氨基烷基哌啶衍生物、制备方法及其用途
CN117430574B (zh) * 2023-12-20 2024-03-22 潍坊医学院 一种苯并呋喃衍生物及其制备方法、用途

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0006524A1 (de) * 1978-06-22 1980-01-09 Ciba-Geigy Ag Neue Tetrahydropyridin- und Piperidinderivate und deren Säureadditionssalze, Verfahren zu deren Herstellung und solche enthaltende pharmazeutische Zusammensetzungen
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5292736A (en) 1993-02-26 1994-03-08 Sterling Winthrop Inc. Morpholinoalkylindenes as antiglaucoma agents
CA2127817C (en) * 1993-07-13 2007-07-03 Hitoshi Tsugaya Tobacco filters and method of producing the same
DE4333254A1 (de) 1993-09-30 1995-04-06 Merck Patent Gmbh Piperidine und Piperazine
US5532237A (en) 1995-02-15 1996-07-02 Merck Frosst Canada, Inc. Indole derivatives with affinity for the cannabinoid receptor
IL117580A0 (en) 1995-03-29 1996-07-23 Merck & Co Inc Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them
DE19514567A1 (de) * 1995-04-20 1996-10-24 Merck Patent Gmbh Benzofurane
FR2741621B1 (fr) 1995-11-23 1998-02-13 Sanofi Sa Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
AU5928898A (en) 1997-01-24 1998-08-18 Regents Of The University Of California, The Use of fxr, pparalpha and lxralpha activators to restore barrier function, promote epidermal differentiation and inhibit proliferation
WO1998041519A1 (en) 1997-03-18 1998-09-24 Smithkline Beecham Corporation Novel cannabinoid receptor agonists
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
JP2003514508A (ja) 1997-07-01 2003-04-15 ノボ ノルディスク アクティーゼルスカブ グルカゴン拮抗剤／逆作用剤
WO1999002499A1 (fr) 1997-07-11 1999-01-21 Japan Tobacco Inc. Composes quinoline et utilisations de ceux-ci en medecine
CA2334551A1 (en) 1998-06-11 1999-12-16 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
DE19837627A1 (de) 1998-08-19 2000-02-24 Bayer Ag Neue Aminosäureester von Arylsulfonamiden und Analoga
WO2000042026A1 (en) 1999-01-15 2000-07-20 Novo Nordisk A/S Non-peptide glp-1 agonists
US6071955A (en) 1999-02-25 2000-06-06 The Regents Of The University Of California FXR, PPARA and LXRA activators to treat acne/acneiform conditions
DE60012721T4 (de) 1999-03-29 2010-09-09 Uutech Ltd., Coleraine Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes
EP1165519A1 (en) 1999-04-02 2002-01-02 Neurogen Corporation Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics
EP1183229B1 (en) 1999-05-17 2005-10-26 Novo Nordisk A/S Glucagon antagonists/inverse agonists
AU766191B2 (en) 1999-06-04 2003-10-09 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
DE19932314A1 (de) * 1999-07-10 2001-01-11 Merck Patent Gmbh Benzofuranderivate
TWI279402B (en) 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same
EP1192182B1 (en) 1999-09-28 2008-06-04 Bayer Corporation Pituitary adenylate cyclase activating peptide (pacap) receptor 3 (r3) agonists and their pharmacological methods of use
DE19958496A1 (de) * 1999-12-04 2001-06-07 Merck Patent Gmbh Verfahren zur Herstellung von 5-(1-Piperazinyl)-benzofuran-2-carboxamid durch Übergangsmetallkatalysierte Aminierung
US6458790B2 (en) 2000-03-23 2002-10-01 Merck & Co., Inc. Substituted piperidines as melanocortin receptor agonists
AU4928101A (en) 2000-03-23 2001-10-03 Merck & Co Inc Spiropiperidine derivatives as melanocortin receptor agonists
WO2001082917A2 (en) 2000-05-03 2001-11-08 Tularik Inc. Treatment of hypertriglyceridemia and other conditions using lxr modulators
US7034039B2 (en) 2001-02-02 2006-04-25 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
EP1383501B1 (en) 2001-02-28 2007-04-04 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
DE10112151A1 (de) * 2001-03-14 2002-09-19 Merck Patent Gmbh Substituierte Benzofuran-2-carbonsäureamide
AR033046A1 (es) 2001-03-22 2003-12-03 Solvay Pharm Bv Derivados de 4,5-dihidro-1h-pirazol que tienen actividad antagonista de cb1, composicion farmaceutica y metodos de preparacion
US6573287B2 (en) 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
FR2824825B1 (fr) 2001-05-15 2005-05-06 Servier Lab Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1406622B1 (en) 2001-06-20 2006-02-22 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
CA2450579A1 (en) 2001-06-20 2003-01-03 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
WO2003000025A2 (en) 2001-06-21 2003-01-03 Champion Microelectronic Corp. Current inrush limiting and bleed resistor current inhibiting in a switching power converter
KR20040015298A (ko) 2001-06-27 2004-02-18 스미스클라인 비참 코포레이션 디펩티딜 펩티다제 억제제로서의 플루오로피롤리딘
CN1471538A (zh) 2001-06-27 2004-01-28 前体生物药物股份有限公司 用于竞争性调节二肽基肽酶iv催化的肽结构
ES2296962T3 (es) 2001-06-27 2008-05-01 Smithkline Beecham Corporation Pirrolidinas como inhibidores de dipeptidil peptidasa.
EP1399433B1 (en) 2001-06-27 2007-08-22 Smithkline Beecham Corporation Fluoropyrrolidines as dipeptidyl peptidase inhibitors
DE60225556D1 (de) 2001-07-03 2008-04-24 Novo Nordisk As Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
AU2002319627A1 (en) 2001-07-20 2003-03-03 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
US6977264B2 (en) 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
KR20020082826A (ko) * 2002-10-12 2002-10-31 박선희 한약재를 이용한 기능성피자의 제조방법
DE10326939A1 (de) * 2003-06-16 2005-01-05 Merck Patent Gmbh Indol-Derivate
DE10326940A1 (de) * 2003-06-16 2005-01-05 Merck Patent Gmbh Indol-Derivate
AU2006325815B2 (en) 2005-12-15 2012-07-05 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
AU2006326135A1 (en) * 2005-12-15 2007-06-21 F. Hoffmann-La Roche Ag Pyrrolo[2,3-c]pyridine derivatives
EP2110374A1 (en) * 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators

Also Published As

Publication number Publication date
IL208322A0 (en) 2010-12-30
CA2721591C (en) 2016-08-09
AU2009238015A1 (en) 2009-10-22
NZ589327A (en) 2012-06-29
CO6311099A2 (es) 2011-08-22
ECSP10010615A (es) 2010-12-30
EP2262785B1 (en) 2015-01-14
EP2262785A1 (en) 2010-12-22
ES2531006T3 (es) 2015-03-09
MY156530A (en) 2016-02-26
US8575161B2 (en) 2013-11-05
EA020454B1 (ru) 2014-11-28
US20110105475A1 (en) 2011-05-05
CN101990535A (zh) 2011-03-23
CA2721591A1 (en) 2009-10-22
EP2110374A1 (en) 2009-10-21
DK2262785T3 (en) 2015-02-16
WO2009127321A1 (en) 2009-10-22
KR20110002478A (ko) 2011-01-07
BRPI0911243A2 (pt) 2015-10-06
HRP20150319T1 (hr) 2015-06-19
CY1116333T1 (el) 2017-02-08
JP2011516589A (ja) 2011-05-26
IL208322A (en) 2016-02-29
BRPI0911243B1 (pt) 2019-10-08
JP2014237676A (ja) 2014-12-18
UA104140C2 (en) 2014-01-10
JP5616326B2 (ja) 2014-10-29
HK1155741A1 (en) 2012-05-25
BRPI0911243B8 (pt) 2021-05-25
ZA201008243B (en) 2012-04-25
EA201001647A1 (ru) 2011-06-30
KR101662853B1 (ko) 2016-10-05
JP5997730B2 (ja) 2016-09-28
PL2262785T3 (pl) 2015-04-30
SI2262785T1 (sl) 2015-05-29
AR071207A1 (es) 2010-06-02
AU2009238015B2 (en) 2013-09-12
MX2010011292A (es) 2010-11-10
CN101990535B (zh) 2013-06-19

Similar Documents

Publication Publication Date Title
PL2262785T3 (pl) Pochodne benzofuranowe jako modulatory FXR
HK1256310A1 (zh) N-磺酰基吡咯衍生物
IL208997A0 (en) Quinolines and related analogs as sirtuin modulators
IL210548A0 (en) Spiroaminodihydrothiazine derivatives
EP2376494A4 (en) DIHYDROPYRIMIDOPIRYMIDINE DERIVATIVES
ZA201100799B (en) Imidazopyridin-2-one derivatives
SG10201506608RA (en) 3-deazaneplanocin derivatives
ZA201100876B (en) Pyrrolopyridinylpyrimidin-2-ylamine derivatives
EP2291078A4 (en) OXAZOLBENZIMIDAZOLDERIVATE
ZA201102449B (en) Morpholinopurine derivatives
HK1158198A1 (en) Novel substituted sulfamide derivatives
EP2279532A4 (en) OXAZOLBENZIMIDAZOLDERIVATE
IL210869A0 (en) Imidazothiadiazoles derivatives
IL208336A0 (en) Pyrisazinone derivatives
IL210613A0 (en) Novel acylaminobenzamide derivatives
IL211290A0 (en) New 2-amidothiadiazole derivatives
ZA201005382B (en) Substituted heteroarylamide diazepinopyrimidone derivatives
IL210164A0 (en) Thiazolylpiperidine derivatives
ZA201005381B (en) Substituted heteroarylamide oxazepinopyrimidone derivatives
ZA201105050B (en) Quinazolinamide derivatives
ZA201008052B (en) 2-phenyl-4-cyclopropyl-pyrimidine derivatives
EP2292613A4 (en) DIHYDROINDOLINONDERIVATE
EP2285794A4 (en) CHROMAN DERIVATIVES AS TRPV3 MODULATORS
IL213051A0 (en) Difluorophenyldiacylhydrazide derivatives
HU0800376D0 (en) Sulfonyl-quinoline derivatives